- Home
- MHH vs TCRX Comparison
MHH vs TCRX Comparison
Compare MHH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHH
- TCRX
- Stock Information
- Founded
- MHH 1986
- TCRX 2018
- Country
- MHH United States
- TCRX United States
- Employees
- MHH N/A
- TCRX N/A
- Industry
- MHH Professional Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MHH Consumer Discretionary
- TCRX Health Care
- Exchange
- MHH Nasdaq
- TCRX Nasdaq
- Market Cap
- MHH 163.5M
- TCRX 170.1M
- IPO Year
- MHH N/A
- TCRX 2021
- Fundamental
- Price
- MHH $13.74
- TCRX $2.43
- Analyst Decision
- MHH
- TCRX Strong Buy
- Analyst Count
- MHH 0
- TCRX 5
- Target Price
- MHH N/A
- TCRX $11.40
- AVG Volume (30 Days)
- MHH 24.3K
- TCRX 285.2K
- Earning Date
- MHH 02-14-2025
- TCRX 03-05-2025
- Dividend Yield
- MHH N/A
- TCRX N/A
- EPS Growth
- MHH N/A
- TCRX N/A
- EPS
- MHH N/A
- TCRX N/A
- Revenue
- MHH $194,248,000.00
- TCRX $9,362,000.00
- Revenue This Year
- MHH $0.53
- TCRX N/A
- Revenue Next Year
- MHH $1.53
- TCRX $5.14
- P/E Ratio
- MHH N/A
- TCRX N/A
- Revenue Growth
- MHH N/A
- TCRX N/A
- 52 Week Low
- MHH $7.15
- TCRX $2.31
- 52 Week High
- MHH $16.00
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- MHH 43.50
- TCRX 33.69
- Support Level
- MHH $13.11
- TCRX $2.39
- Resistance Level
- MHH $14.75
- TCRX $2.67
- Average True Range (ATR)
- MHH 0.84
- TCRX 0.16
- MACD
- MHH -0.12
- TCRX 0.04
- Stochastic Oscillator
- MHH 8.30
- TCRX 28.74
About MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.